| abstract |
The authors of the present invention have found a method for enhancing the endogenous production of anti-inflammatory cytokines, such as interleukin-10 (IL-10), in mammalian cells or tissues, comprising administering to a subject, preferably a human subject, in need thereof an effective amount of a LRH-1 agonist according to the invention or a pharmaceutically acceptable salt thereof. This method is shown in the present specification as particularly suitable for treating diseases wherein immunomodulation by an increase in the secretion of anti-inflammatory cytokines, such as IL-10, is desirable, for instance for the treatment of cancer and anti-inflammatory diseases such as type I diabetes, in particular early stage type I diabetes, type II diabetes and autoimmune hepatitis. |